NCT00239174已完成2 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multi-Center Study Evaluating the Efficacy and Safety of Four Doses of SR147778 in Obese Patients
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 394
- 试验地点
- 5
- 主要终点
- Weight loss at 6 months.
研究概览
简要总结
The purpose of this study is to assess the effect of SR147778 on weight loss over a period of 24 weeks when prescribed with a hypocaloric diet in obese patients. The secondary objective is to assess the safety and tolerability of SR147778 and to assess the effect of SR147778 on several secondary parameters (such as waist, metabolic parameters) over a period of 24 weeks when prescribed with a hypocaloric diet in obese patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must voluntarily sign the informed consent,
- •Patients must be male or female and aged 18 to 65 years,
- •Patients must be able to follow verbal and written instructions,
- •Female patients of childbearing potential (pre-menopausal women) must have a confirmed negative urine b-hCG pregnancy test prior to enrollment and Baseline Visit. They must use an acceptable double method of birth control (e.g., oral or implanted contraceptive therapy, or IUDs, plus a barrier such as condom, diaphragm or spermicide) throughout the study, and accept to repeat urine b-hCG pregnancy test at designated visits,
- •Patients must have a BMI >=30 and <= 40 at screening
- •Patients must have had a stable weight (variation of less than 5 kg during the 90 days preceding the Screening Visit)
- •Patients must have shown to be compliant to dietary recommendations between the Screening and the Baseline Visits
- •Patients' physical examination, laboratory evaluations, 12-lead ECG must be within normal limits (with the exception of abnormalities considered as clinically insignificant in the opinion of the Investigator and the Center Monitor), or within predefined limits for hemoglobin (>= 11 g/dL), total cholesterolemia (<= 3 g/L, i.e. 7.7 mmol/L), triglyceridemia (<= 7 g/L, i.e. 7.9 mmol/L), fasting glycemia (<= 1.6 g/L, i.e. 8.9 mmol/L), and hemoglobin A1c (<= 8%).
排除标准
- •Female patients who are pregnant or lactating,
- •Patients who are considered by the Investigator to be unsuitable candidates for receipt of an investigational drug,
- •Myocardial infarction within 12 months,
- •Hypertension (SBP > 160 mmHg; DBP > 95 mmHg),
- •Secondary hypertension- Confirmed heart rate < 60 beats/minute,
- •Type 1 diabetes, or treated with insulin
- •History or presence of pancreatitis,
- •History or presence of clinically significant cardiac valve disorder or abnormal cardiac echography.
- •History or concurrent DSM-IV bulimia or anorexia nervosa,
- •Patients with mental retardation or any clinically significant psychiatric disorder (including organic mental disorder) other than mild mood or anxiety,
- •History (during the past six months) or concurrent DSM-IV substance abuse or dependence (excluding nicotine and caffeine as far as patient agrees not to modify her/his consumption throughout the study),
- •Severe or multiple drug allergies,
- •Any disorder that may interfere with drug absorption, metabolism distribution or excretion,
- •Presence of any clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, dermatological or respiratory disease, or any other medical condition that might interfere with the evaluation of study medication,
- •Prolonged QTcB: > 450 msec for men and > 470 msec for women.
- •Patients who test positive for any illicit drug included in the urine drug screen (THC) at the Screening or the Baseline Visit. Patients positive for benzodiazepines only may be admitted, if prescribed with stable dose regimen.
- •Patients who test positive at the Screening Visit for hepatitis B surface antigen, hepatitis C antibody, or ALT and/or AST > 2 x upper limit of normal,
- •Hb < 11g/dL, fasting glycemia > 1.6 g/L i.e. 8.9 mmol/L, HbA1c > 8%, total cholesterolemia > 3 g/L i.e. 7.7 mmol/L, or TG > 7 g/L i.e. 7.9 mmol/L, creatinemia > 150 mmol/l- Patients who have received anti-obesity drugs or other drug(s) or preparation(s) including herbal for weight reduction within three months of Screening Visit,
- •Thyroid therapy, except on replacement therapy.
- •Patients using nicotine substitutes or taking bupropion,
- •Treated with antidepressant or neuroleptics drug(s) for more than one week within three months of Screening Visit,
- •Treated with non selective systemic antihistamines
- •Systemic corticosteroids or inhaled corticosteroids
- •Treated with potent inhibitors of CYP3A4
- •Consuming more than 20 g/day of alcohol.
结局指标
主要结局
Weight loss at 6 months.
次要结局
- Waist circumference,lipid parameters,glycemic parameters,metabolic syndrome,blood pressure,adipokines,CRP,IL-6,IL-2,patient satisfaction,food behavior,daily caloric intake, and dietary compliance at 6 months.
研究者
研究点 (5)
Loading locations...
相似试验
已完成
3 期
Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)ObesityNCT00386061Sanofi1,507
已完成
3 期
Obese Patients With Untreated DyslipidemiasObesityDyslipidemiaNCT00029835Sanofi1,033
已完成
3 期
Obese Patients With Type 2 DiabetesDiabetes Mellitus, Non-Insulin-DependentObesity in DiabetesObesityNCT00029848Sanofi1,045
已完成
4 期
Phase IV Study of Qsymia in Obese PatientsObesityNCT05378503Alvogen Korea232
已完成
2 期
An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese SubjectsObesityNCT01666691Zafgen, Inc.160